Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.

Blood - 4 Nov 2010

Alchalby Haefaa, Badbaran Anita, Zabelina Tatjana, Kobbe Guido, Hahn Joachim, Wolff Daniel, Bornhäuser Martin, Thiede Christian, Baurmann Herrad, Bethge Wolfgang, Hildebrandt York, Bacher Ulrike, Fehse Boris, Zander Axel R, Kröger Nicolaus

Abstract excerpt

Allogeneic stem cell transplantation (ASCT) after reduced-intensity conditioning has become a reasonable treatment option for patients with advanced myelofibrosis. The role of characteristic molecular genetic abnormalities, such as JAK2V617F on outcome of ASCT, is not yet elucidated. In 139 of 16...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Janus Kinase 2
Share to Primary Myelofibrosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Recurrence

Share to Stem Cell Transplantation

Share to Survival Analysis

Share to Transplantation Conditioning

Share to Transplantation, Homologous

Share to Treatment Outcome

Source

Identifiers

PMID: 20489052
DOI: 10.1182/blood-2009-12-260588

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20489052-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.PMID 20489052Read ↗

JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse.Semantic proximity Read ↗

Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell TransplantationSemantic proximity Read ↗

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.Semantic proximity Read ↗

Allogeneic hematopoietic cell transplantation for patients with myelofibrosis.Semantic proximity Read ↗

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival.Semantic proximity Read ↗

Clinical relevance of JAK2 (V617F) mutant allele burden.Semantic proximity Read ↗

The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders.Semantic proximity Read ↗

Eradication of JAK2 V617F mutation after allogeneic transplantation in a patient with myelofibrosis with myeloid metaplasia.Semantic proximity Read ↗

Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosisSemantic proximity Read ↗

Safety and outcome of allogeneic stem cell transplantation in myelofibrosis.Semantic proximity Read ↗

JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.